US2010240037A1PendingUtilityA1

Identification of markers in esophageal cancer, colon cancer, head and neck cancer, and melanoma

62
Individually held — no corporate assignee on recordPriority: Jul 9, 2004Filed: Dec 15, 2009Published: Sep 23, 2010
Est. expiryJul 9, 2024(expired)· nominal 20-yr term from priority
Inventors:Tony GodfreyLiqiang XiSiva RajaSteven J. HughesWilliam E. Gooding
C12Q 1/6886C12Q 2600/16C12Q 2600/158C12Q 2600/112
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for identifying expression of markers indicative of the presence of esophageal, a squamous cell cancer, a squamous cell cancer of the head and neck, colon cancer and melanoma are provided. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods.

Claims

exact text as granted — not AI-modified
1 . A method of identifying expression of markers indicative of the presence of esophageal cancer cells in a lymph node of a patient, comprising determining if a first mRNA species specific to one of CEA, CK19, CK20, TACSTD1, VIL1, PVA and CK7 is overabundant in an RNA sample prepared from the lymph node, provided when the first mRNA species is CEA, the method further comprises determining if a second mRNA species specific to CK19 is overabundant in an RNA sample prepared from the lymph node, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         2 . The method of  claim 1 , further comprising determining if one or more additional mRNA species, different from the first mRNA species, specific to one or more of CEA, CK19, CK20, TACSTD1, VIL1, PVA and CK7 is overabundant in the RNA sample, the overabundance of the first mRNA species and the one or more additional mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         3 . The method of  claim 1 , wherein the first mRNA species is specific to CK19 and a second mRNA species is specific CEA. 
     
     
         4 . The method of  claim 1 , wherein the first mRNA species is specific to CK20. 
     
     
         5 . The method of  claim 4 , further comprising determining if a second mRNA species specific to CK19 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         6 . The method of  claim 1 , wherein the first mRNA species is specific to TACSTD1. 
     
     
         7 . The method of  claim 6 , further comprising determining if a second mRNA species specific to CEA is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         8 . The method of  claim 6 , further comprising determining if a second mRNA species specific to CK7 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         9 . The method of  claim 6 , further comprising determining if a second mRNA species specific to CK19 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         10 . The method of  claim 6 , further comprising determining if a second mRNA species specific to CK20 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         11 . The method of  claim 6 , further comprising determining if a second mRNA species specific to VIL1 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         12 . The method of  claim 1 , wherein the first mRNA species is specific to VIL1. 
     
     
         13 . The method of  claim 12 , further comprising determining if a second mRNA species specific to CK19 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced esophageal cells in the lymph node. 
     
     
         14 . The method of  claim 1 , wherein the first mRNA species is specific to CK7. 
     
     
         15 . The method of  claim 1 , wherein the first mRNA species is specific to PVA. 
     
     
         16 - 24 . (canceled) 
     
     
         25 . A method of identifying expression of markers indicative of the presence of cells of a squamous cell carcinoma of the head & neck in a lymph node of a patient, comprising determining if a first mRNA species specific to one of CEA, CK19, PTHrP, TACSTD1 and SCCA1.2 is overabundant in an RNA sample prepared from the lymph node, the overabundance of the mRNA species being indicative of the presence of displaced cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         26 . The method of  claim 25 , wherein the first mRNA species is specific to CEA. 
     
     
         27 . The method of  claim 25 , wherein the first mRNA species is specific to PTHrP. 
     
     
         28 . The method of  claim 27 , further comprising determining if a second mRNA species specific to SCCA1.2 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         29 . The method of  claim 27 , further comprising determining if a second mRNA species specific to PVA is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         30 . (canceled) 
     
     
         31 . The method of  claim 25 , wherein the first mRNA species is specific to PVA and further comprising determining if a second mRNA species specific to SCCA1.2 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         32 . The method of  claim 25 , wherein the first mRNA species is specific to CK19. 
     
     
         33 . The method of  claim 25 , wherein the first mRNA species is specific to TACSTD1. 
     
     
         34 . The method of  claim 33 , further comprising determining if a second mRNA species specific to SCCA1.2 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         35 . The method of  claim 33 , further comprising determining if a second mRNA species specific to PVA is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         36 . The method of  claim 33 , further comprising determining if a second mRNA species specific to PTHrP is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of displaced cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         37 . The method of  claim 25 , wherein the first mRNA species is specific to SCCA1.2. 
     
     
         38 . The method of  claim 25 , further comprising determining if one or more additional mRNA species, different from the first mRNA species, specific to one or more of CEA, CK19, PTHrP, PVA, TACSTD1 and SCCA1.2 is overabundant in the RNA sample, the overabundance of the first mRNA species and the one or more additional mRNA species being indicative of the presence of cells of a squamous cell carcinoma of the head & neck in the lymph node. 
     
     
         39 . The method of  claim 25 , comprising quantifying levels of the mRNA species in the RNA sample and determining if one or more of the mRNA species are overabundant in the RNA sample. 
     
     
         40 - 47 . (canceled) 
     
     
         48 . A method of identifying expression of markers indicative of the presence of cells of a squamous cell carcinoma in a lymph node of a patient, comprising determining if a first mRNA species specific to PVA is overabundant in an RNA sample prepared from the lymph node, the overabundance of the mRNA being indicative of the presence of displaced cells of a squamous cell carcinoma in the lymph node. 
     
     
         49 . A method of identifying expression of markers indicative of the presence of colon cancer cells in a lymph node of a patient, comprising determining if a first mRNA species specific to one of CDX1, TACSTD1 and VIL1 is overabundant in an RNA sample prepared from the lymph node, the overabundance of the first mRNA species being indicative of the presence of displaced colon cells in the lymph node. 
     
     
         50 . The method of  claim 49 , wherein the first mRNA species is specific to CDX1. 
     
     
         51 . The method of  claim 49 , wherein the first mRNA species is specific to TACSTD1. 
     
     
         52 . The method of  claim 49 , wherein the first mRNA species is specific to VIL1. 
     
     
         53 . The method of  claim 49 , comprising quantifying levels of the mRNA species in the RNA sample and determining if one or more of the mRNA species are overabundant in the RNA sample. 
     
     
         54 - 61 . (canceled) 
     
     
         62 . The method of  claim 49 , further comprising determining if one or more additional mRNA species, different from the first mRNA species, specific to one or more of CDX1, CEA, CK19, CK20, TACSTD1, and VIL1 are overabundant in the RNA sample, the overabundance of the first mRNA species and the one or more additional mRNA species being indicative of the presence of displaced colon cells in the lymph node. 
     
     
         63 . A method of identifying expression of markers indicative of the presence of melanoma cells in a lymph node of a patient, comprising determining if a first mRNA species specific to a MAGEA136-plex is overabundant in an RNA sample prepared from the lymph node, the overabundance of the first mRNA species being indicative of the presence of melanoma cells in the lymph node. 
     
     
         64 . The method of  claim 63 , further comprising determining if a second mRNA species specific to MART1 is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of melanoma cells in the lymph node. 
     
     
         65 . The method of  claim 63 , further comprising determining if a second mRNA species specific to TYR is overabundant in the RNA sample, the overabundance of the mRNA species being indicative of the presence of melanoma cells in the lymph node. 
     
     
         66 - 87 . (canceled)

Join the waitlist — get patent alerts

Track US2010240037A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.